Bioverativ, A Sanofi Company

This study tested a new long-acting treatment called BIVV001 for people with severe Hemophilia A, a condition where blood doesn't clot properly. The goal was to see if a single weekly injection could safely prevent bleeding episodes and treat bleeds when they happen. The trial in…

This study tested an experimental drug called BIVV020 in 12 adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The main goal was to see if BIVV020 could safely help increase and maintain platelet counts over a l…

This small, early-stage study tested a single dose of an experimental drug called BIVV020 in 12 adults with cold agglutinin disease, a rare autoimmune blood disorder. The main goal was to check the drug's safety and how well it was tolerated. Researchers also measured how the dru…

This was a very early, first-in-human study to see how the body processes a single dose of an experimental drug called BIVV001 and to check if it is safe. It involved just 6 adults with severe forms of a rare inherited bleeding disorder called von Willebrand disease. The main goa…

This study tested a new, long-acting factor VIII replacement drug called BIVV001 in children under 12 with severe hemophilia A. The main goal was to see if it was safe and effective at preventing and treating bleeding episodes over a year of treatment. Researchers also looked at …

This study tested an experimental drug called SAR445088 in adults with CIDP, a rare condition that causes progressive weakness and numbness. The main goal was to see if the drug could control the disease and prevent relapses in different groups of patients, including those who do…